RBC Capital Maintains Outperform on Couchbase, Lowers Price Target to $18

RBC Capital analyst Matthew Hedberg maintains Couchbase (NASDAQ:BASE) with a Outperform and lowers the price target from $20 to $18.

byBenzinga Newsdesk

December 7, 2022

1 minute read

RBC Capital analyst Matthew Hedberg maintains Couchbase (NASDAQ:BASE) with a Outperform and lowers the price target from $20 to $18.

Northland Capital Markets Upgrades Protagonist Therapeutics to Outperform, Announces $40 Price Target

By Benzinga Newsdesk

October 11, 10:11 AM

Northland Capital Markets analyst Tim Chiang upgrades Protagonist Therapeutics (NASDAQ:PTGX) from Market Perform to Outperform and announces $40 price target.

PTGX

Why McKesson Shares Are Jumping Today

By Vandana Singh

May 6, 2:31 PM

McKesson Corp (NYSE:MCK) reported Q4 FY22 adjusted EPS of $5.83, +15% Y/Y, and missing the consensus of $6.04. Revenues increased…

MCK

News

Titan Medical Granted Patent Covering User Experience, Further Enhancing Its Intellectual Property In Robotic Assisted Surgery

By Benzinga Newsdesk

December 13, 8:35 AM

Titan Medical Inc. (NASDAQ:TMDI, TSX:TMD), a medical device company focused on the development and commercialization of innovative surgical technologies for single access robotic-assisted surgery (RAS), today announced

TMDI